Experimental Lung Cancer Drug Shows 34% Reduction in Death Risk

Breakthrough Results in Squamous Non-Small-Cell Lung Cancer

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial. The company released results on Sunday ahead of a presentation at the American Society of Clinical Oncology’s annual meeting. When combined with chemotherapy, the drug kept people with squamous non-small-cell lung cancer alive for a median of four months longer than the standard combination of immunotherapy and chemotherapy.

Researchers conducted the Phase 3 trial in China. They are currently running a global Phase 3 study. The result was statistically significant, according to an abstract released Sunday. The trial focused on a difficult-to-treat patient population, making the survival improvement particularly noteworthy.

“The fact that it shows an improvement in overall survival in a difficult-to-treat patient population is very encouraging,” said Dr. Suresh Ramalingam, executive director of the Winship Cancer Institute of Emory University. “I’m mindful of the fact that this trial was done exclusively in China, and that brings up the question of how do these data apply to patient populations outside of China, and that will require future investigations.”

How Ivonescimab Works Differently

The drug, called ivonescimab, is a bispecific antibody that targets two distinct proteins. It targets PD-1, similar to Merck’s best-selling drug Keytruda. It also targets VEGF, similar to Roche’s Avastin. PD-1 is a protein that helps cancer cells hide from the immune system. VEGF is a protein that promotes the growth of new blood vessels and can help cancer cells thrive.

The drug has become the subject of intense debate in the oncology and investment communities. Some experts say ivonescimab and similar drugs could be a successor to Merck’s wildly successful cancer drug Keytruda. Others warn it’ll disappoint like other once-promising ideas such as drugs targeting TIGIT, an immune receptor.

Market Reaction and Investor Concerns

The dueling narratives are reflected in the stock price of U.S.-based Summit Therapeutics. The company licensed the rights to ivonescimab outside of China from Akeso. Shares of Summit have skyrocketed nearly 600% in the two years since significant trial results emerged. Summit announced that ivonescimab more effectively controlled tumors than Keytruda in a separate China trial.

The stock has slid in the past month over concerns the drug won’t be as effective in a global population. Investors remain cautious about whether results from Chinese patients will translate to diverse populations worldwide. This geographic limitation creates uncertainty about regulatory approval in Western markets.

Why Overall Survival Matters

Previous studies showed ivonescimab can effectively control tumors. This endpoint is known as progression-free survival. That’s typically not enough to seek approval from the U.S. Food and Drug Administration. The FDA wants proof that cancer drugs can keep people alive longer. Older VEGF drugs that effectively controlled tumors struggled to improve survival rates.

The current results are particularly significant because they demonstrate an overall survival benefit, not just tumor control. The 34% reduction in death risk meets the FDA’s gold standard for cancer drug approval. This distinction separates ivonescimab from previous treatments that showed promise but failed to extend patient lives.

Global Trial Will Determine Future

The ongoing global Phase 3 study is crucial for regulatory approval outside China. It will provide results from diverse patient populations. This addresses concerns about geographic limitations. If ivonescimab demonstrates similar efficacy globally, it could transform lung cancer treatment.

The global study tests whether the drug’s performance in Chinese patients translates to other ethnic groups and healthcare settings. Genetic differences, environmental factors, and treatment practices vary significantly between regions. These variables can affect drug efficacy and safety profiles. Regulators in the United States and Europe will scrutinize the global trial data carefully.

Implications for Cancer Treatment Landscape

Ivonescimab’s dual-targeting approach represents a new generation of cancer immunotherapy. Traditional treatments like Keytruda focus on a single pathway. By targeting both PD-1 and VEGF simultaneously, the bispecific antibody attacks cancer through multiple mechanisms. This strategy could overcome resistance that develops with single-target therapies.

Squamous non-small-cell lung cancer remains one of the deadliest cancer types. Patients have limited treatment options after first-line therapy fails. The four-month survival improvement, while modest, represents meaningful additional time for patients and families. Any extension of life in this aggressive cancer type is considered clinically significant.

The pharmaceutical industry watches these developments closely. Keytruda generates over $25 billion in annual revenue for Merck. A successor drug that improves upon Keytruda’s efficacy could capture substantial market share. However, pricing, manufacturing capabilities, and patent protections will all influence commercial success.

Next Steps and Timeline

Researchers will present full trial data at the upcoming American Society of Clinical Oncology meeting. The detailed results will reveal important safety information and subgroup analyses. Oncologists want to know which patient populations benefit most from the treatment. They also need data on side effects and quality of life measures.

Summit Therapeutics and Akeso must complete their global trial before seeking regulatory approval. The timeline for approval in Western markets remains uncertain. Even with positive results, the approval process typically takes several years. The companies face competition from other experimental treatments in development.